Legend Biotech Announces Carvykti Approved By The European Commission For Second-Line Treatment Of Patients With Relapsed And Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Legend Biotech Corporation (NASDAQ:LEGN) announced the European Commission's approval of CARVYKTI for the treatment of adult patients with relapsed and refractory multiple myeloma. This approval, based on the positive results of the CARTITUDE-4 study, marks a significant advancement in the treatment of this incurable disease. The application for this approval was submitted by Janssen-Cilag International N.V., an affiliate of Janssen Biotech, Inc., a Johnson & Johnson company, which collaborates with Legend Biotech on CARVYKTI.
April 22, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech's CARVYKTI receives European Commission approval for treating relapsed and refractory multiple myeloma, indicating a significant advancement in treatment options.
The European Commission's approval of CARVYKTI represents a significant milestone for Legend Biotech, potentially increasing the company's market presence in Europe and enhancing its reputation in the biotech industry. This approval, based on the positive outcomes of the CARTITUDE-4 study, could lead to increased demand for CARVYKTI, positively impacting Legend Biotech's stock in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100